Rein Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$50.6M | -$65.1M | -$16.3M | -$27.6M | -$26.6M |
| Operating expenses | $50.6M | $65.1M | $16.3M | $27.6M | $26.6M |
| Cash from operations | -$19.4M | -$22.3M | -$19.8M | -$24.9M | -$23.8M |
| Capital expenditure | — | — | — | — | $157,000 |
| Free cash flow | — | — | — | — | -$23.9M |
| Impairments | $0 | $0 | $0 | — | — |
| Total assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M |
| Total liabilities | $7.2M | $7.8M | $7.7M | $3.4M | $4.6M |
Shares outstanding 85.5M · Free float 92.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.